Lacidipino Teva (Lacidipine)

Lacidipine is a calcium channel blocker used in the management of high blood pressure and related cardiovascular conditions.

• Hypertension: reduces elevated systolic and diastolic blood pressure.
• Primary hypertension: helps achieve target blood pressure levels in essential hypertension.
• Secondary hypertension: can be added to other therapies when blood pressure elevation is due to an identifiable cause.

• Lacidipine selectively inhibits L‑type calcium channels on vascular smooth‑muscle cells, decreasing calcium influx. This leads to relaxation of arterial smooth muscle, vasodilation, and a consequent reduction in systemic vascular resistance and arterial blood pressure.

Lacidipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity.
• Flushing: transient warmth and redness of the skin.
• Peripheral edema: swelling of the ankles or feet.
• Dizziness or light‑headedness, especially after standing.
• Nausea or abdominal discomfort.
• Tachycardia: increased heart rate.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure causing fainting.
• Angioedema: swelling of the face, lips, tongue, or throat.
• Myocardial infarction: rare occurrence of heart attack.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Allergic reactions: rash, pruritus, or urticaria.
• Blood dyscrasias: rare blood cell abnormalities.

Before prescribing Lacidipino Teva, clinicians should consider several safety aspects.

• Blood pressure monitoring: check baseline and follow‑up readings.
• Liver function: assess hepatic enzymes in patients with liver disease.
• Concomitant antihypertensives: adjust doses to avoid excessive hypotension.
• Elderly patients: start at lower dose and monitor for dizziness.
• Discontinuation: avoid abrupt cessation; taper if long‑term therapy is stopped.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lacidipine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase lacidipine levels.
• Other calcium channel blockers: additive vasodilatory effect leading to hypotension.
• Grapefruit juice: can raise plasma concentrations.
• Concurrent antihypertensives with potent vasodilatory action: risk of severe hypotension.
• Rifampicin or other CYP3A4 inducers: may reduce therapeutic effect.

Moderate Interactions (Monitor Closely):\n- NSAIDs: may blunt antihypertensive response.

• Diuretics: may increase risk of electrolyte imbalance.
• Beta‑blockers: monitor heart rate and blood pressure.
• ACE inhibitors or ARBs: watch for additive blood pressure lowering.
• Lipid‑lowering agents (e.g., statins metabolized by CYP3A4): monitor for increased statin exposure.